huC242-DM4: Additional Phase I data

Additional data from a Phase I trial showed that the MTD of huC242-DM4 was 168 mg/m 2 given every 3 weeks. At a higher dose (223 mg/m 2), there were 2 cases of reduced visual acuity. Six of 26 evaluab...